Nykode Therapeutics AS (VACBF PINK) stock market data APIs
$0.4533
0(0%)
as of September 18, 2026
Try our APIs with
free plan!
Nykode Therapeutics AS Financial Data Overview
Price chart is built with
Anychart
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Prev. Close
0.4533
Open
0.4533
High
0.4533
Low
0.4533
52 wk Range
0.1558-0.4542
Market Cap
178 M
Shares Outstanding
392 M
Revenue
464 K
EPS
-0.022
Beta
0.842
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nykode Therapeutics AS data using free add-ons & libraries
Get Nykode Therapeutics AS Fundamental Data
Nykode Therapeutics AS Fundamental data includes:
- Net Revenue: 464 K
- EBITDA: -26 937 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nykode Therapeutics AS News
New
Nykode Therapeutics AS (VACBF) (Q2 2026) Earnings Call Highlights: Strategic Advances and ...
This article first appeared on GuruFocus. Other Income: $106,000 for Q2 2026, related to government grants. Employee Benefit Expenses: $2.3 million in Q2 2026, down from $2.9 million in Q2 2025, refl...
European Penny Stocks To Watch In January 2026
The European markets have recently faced a downturn, with the pan-European STOXX Europe 600 Index and major national indices like France’s CAC 40 and Germany’s DAX experiencing declines amid renew...
3 European Penny Stocks With Market Caps Up To €1B
As the pan-European STOXX Europe 600 Index edges closer to record highs, optimism about future earnings and economic prospects is creating a favorable backdrop for investors. Penny stocks, although an...
European Penny Stocks To Watch In November 2025
Amidst renewed concerns over inflated AI stock valuations, European markets have experienced a downturn, with the pan-European STOXX Europe 600 Index declining by 2.21%. Despite these broader market c...
Get Nykode Therapeutics AS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
